Impax Laboratories Inc. v. Lannett Holdings Inc., No. 17-2020 (Fed. Cir. June 28, 2018)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Lannett Holdings Inc. and Lannett Co. Inc. (together, “Lannett”) appeal from the decision of the United States District Court for the District of Delaware concluding, after a bench trial, that claims 4, 11, 12, and 14 of U.S. Patent 6,760,237 (“the ’237 patent”) and claims 6 and 14– 16 of U.S. Patent 7,220,767 (“the ’767 patent”) were not shown to be invalid, see Impax Labs., Inc. v. Lannett Holdings Inc., 246 F. Supp. 3d 1024 (D. Del. 2017) (“ Opin- ion”), entering judgment in favor of Impax Laboratories Inc.